NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CC stock has decreased by 10.7% and is now trading at $9.52. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Chemours.

Chemours Co (NYSE:CC) issued its earnings results on Thursday, February, 13th. The specialty chemicals company reported $0.56 EPS for the quarter, beating the Zacks' consensus estimate of $0.42 by $0.14. The specialty chemicals company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.37 billion. Chemours had a positive return on equity of 52.65% and a negative net margin of 0.92%. View Chemours' earnings history.

Chemours announced a quarterly dividend on Wednesday, February 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.25 per share on Monday, March 16th. This represents a $1.00 annualized dividend and a yield of 10.50%. The ex-dividend date of this dividend is Wednesday, February 26th. View Chemours' dividend history.

Chemours issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of $2.60-$3.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.22.

12 Wall Street analysts have issued 1-year target prices for Chemours' shares. Their forecasts range from $10.00 to $42.00. On average, they expect Chemours' share price to reach $18.95 in the next twelve months. This suggests a possible upside of 99.1% from the stock's current price. View analysts' price targets for Chemours.

Media headlines about CC stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemours earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutChemours.

Chemours saw a increase in short interest in March. As of March 13th, there was short interest totaling 16,479,800 shares, an increase of 10.5% from the February 27th total of 14,910,000 shares. Based on an average trading volume of 3,190,000 shares, the days-to-cover ratio is presently 5.2 days. Currently, 10.2% of the shares of the stock are sold short. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), Balchem (BCPC), Ashland Global (ASH), W. R. Grace & Co (GRA), Univar (UNVR), Olin (OLN), Ingevity (NGVT), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), Intel (INTC) and Johnson & Johnson (JNJ).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.02%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View institutional ownership trends for Chemours.

CC stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher. View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $9.52.

Chemours has a market capitalization of $1.56 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe. View additional information about Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]